Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ViroPharma board OKs extra $200M stock buyback

This article was originally published in Scrip

ViroPharma's board of directors has approved an additional $200 million to repurchase shares of its shares and/or its 2% senior convertible notes due 2017.

The Exton, Pennsylvania-based company also said that it has mostly completed a $150 million securities buyback announced in March. ViroPharma repurchased approximately 8.1 million shares of common stock using $149 million of the $150 million authorised. The firm had approximately 70.8 million outstanding shares as of 13 September.

The expanded stock repurchase programme "demonstrates our confidence in the future prospects of our existing business", said chief financial officer Charles Rowland.

ViroPharma markets products for hereditary angioedema and Clostridium difficile infection. Most recently, it was granted a paediatric use marketing authorisation from the European Commission for its Buccolam (midazolam, fixed-dose oromucosal solution) for prolonged acute convulsions in paediatric patients (7 September 2011).

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC014473

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel